암 치료 분야 유전체학 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 기술별, 용도별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
Genomics in Cancer Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Application, By End User, By Region and Competition, 2020-2030F
암 치료 분야 유전체학 세계 시장 규모는 2024년 157억 3,000만 달러로 평가되었고, 예측 기간 동안 402억 2,000만 달러에 달할 것으로 예상되며, 2030년까지 16.91%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.
세계 암 치료 분야 유전체학 시장은 정밀의료의 보급과 유전체 기술의 발전으로 큰 성장을 거듭하고 있습니다. 암 진단 및 치료에 있어 차세대 염기서열분석기(NGS), 액체생검, 인공지능의 통합은 암 치료를 혁신적으로 변화시켰습니다. 암 발병률 증가와 개인 맞춤형 치료에 대한 요구가 높아지면서 유전체 기반 솔루션에 대한 수요가 가속화되고 있습니다. 제약사, 연구기관, 진단업체들은 바이오마커 기반 암 치료제를 개발하기 위해 협력하여 치료 효과와 환자 예후를 개선하고 있습니다. 유전체 데이터 분석 도구와 바이오인포매틱스 플랫폼의 지속적인 발전은 시장 확대를 더욱 촉진하고 있으며, 유전체 분석은 현대 암 치료에 필수적인 요소로 자리 잡고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
157억 3,000만 달러 |
| 시장 규모 : 2030년 |
402억 2,000만 달러 |
| CAGR : 2025-2030년 |
16.91% |
| 급성장 부문 |
맞춤형 의료 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
유전체 시퀀싱의 발전
주요 시장 이슈
비용과 접근성
주요 시장 동향
액체생검과 조기발견
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 암 치료 분야 유전체학 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 제품별(기기, 소모품, 서비스)
- 기술별(유전체 시퀀싱, PCR, 마이크로어레이, 핵산 추출, 정제, 기타)
- 용도별(진단, 맞춤형 의료, Drug Discovery & Development, 조사)
- 최종사용자별(병원, 연구기관, 학술기관, 기타)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 암 치료 분야 유전체학 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 암 치료 분야 유전체학 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 암 치료 분야 유전체학 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 암 치료 분야 유전체학 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 암 치료 분야 유전체학 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
- 인수합병(M&A)(해당하는 경우)
- 제품 발매(해당하는 경우)
- 최근 동향
제13장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제14장 경쟁 구도
- Illumina Inc
- Agilent Technologies, Inc.
- Roche Diagnostics
- Cancer Genetics, Inc.
- Bio-Rad Laboratories Inc
- Sigma-Aldrich Corp
- QIAGEN NV
- GE Healthcare Inc
- Life Technologies Corp
- Quest Diagnostics Inc
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Genomics in Cancer Care Market was valued at USD 15.73 Billion in 2024 and is expected to reach USD 40.22 Billion in the forecast period with a CAGR of 16.91% through 2030. The Global Genomics in Cancer Care Market is experiencing significant growth due to the increasing adoption of precision medicine and advancements in genomic technologies. The integration of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence in cancer diagnostics and treatment has transformed oncology care. Rising cancer prevalence and the growing need for personalized therapies have accelerated the demand for genomic-based solutions. Pharmaceutical companies, research institutions, and diagnostic firms are collaborating to develop biomarker-driven cancer therapies, enhancing treatment efficacy and patient outcomes. The continuous evolution of genomic data analysis tools and bioinformatics platforms further supports the market's expansion, making genomics an essential component of modern cancer care.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 15.73 Billion |
| Market Size 2030 | USD 40.22 Billion |
| CAGR 2025-2030 | 16.91% |
| Fastest Growing Segment | Personalized Medicine |
| Largest Market | North America |
Key Market Drivers
Advancements in Genomic Sequencing
In the ever-evolving landscape of cancer care, genomic sequencing has emerged as a potent tool, significantly shaping the Global Genomics in Cancer Care Market. Advancements in genomic sequencing, particularly Next-Generation Sequencing (NGS), have enabled comprehensive molecular profiling of cancer. This allows researchers and healthcare providers to analyze a patient's entire genome to identify mutations, alterations, and genetic markers associated with cancer, facilitating more accurate diagnoses and tailored treatment strategies.
The Cancer Genome Atlas (TCGA), a landmark program by the National Cancer Institute (NCI), has molecularly characterized over 20,000 primary cancer and matched normal samples across 33 cancer types. This extensive dataset, comprising more than two petabytes of genomic data, is publicly available and aids the cancer research community in improving prevention, diagnosis, and treatment strategies.
Genomic sequencing allows for the identification of specific genetic mutations driving a patient's cancer, which is invaluable in developing targeted therapies. Pharmaceutical companies leverage genomic insights to create drugs that precisely target the genetic abnormalities responsible for cancer growth, increasing treatment effectiveness and reducing side effects.
Personalized medicine, based on genomic sequencing, has revolutionized cancer care. By analyzing a patient's genetic makeup, oncologists can tailor treatment plans to the individual, optimizing therapy selection and dosage. This approach not only improves patient outcomes but also enhances the overall quality of life during treatment.
Genomic sequencing also plays a crucial role in early detection and prevention. Genetic testing can identify individuals with a higher risk of developing certain cancers, enabling early interventions and proactive health management. Additionally, screening for genetic markers associated with cancer allows for earlier diagnosis and intervention, increasing the chances of successful treatment.
The wealth of data generated through genomic sequencing is a goldmine for researchers and healthcare providers. Advanced data analytics and bioinformatics tools are employed to interpret and extract meaningful insights from genomic data, leading to more informed clinical decisions and supporting ongoing research into new cancer therapies and diagnostic tools.
Advancements in genomic sequencing have driven down the cost of sequencing, making it more accessible for patients and healthcare providers. As sequencing becomes more affordable, its adoption in clinical settings becomes more widespread, further fueling market growth.
In summary, the integration of genomic sequencing into cancer care has transformed the approach to diagnosis, treatment, and prevention, driving significant advancements in the Global Genomics in Cancer Care Market.
Key Market Challenges
Cost and Accessibility
The high cost of genomic technologies and limited accessibility to advanced cancer care remain significant challenges in the Global Genomics in Cancer Care Market. Next-generation sequencing (NGS), whole genome sequencing, and other genomic profiling techniques require expensive instruments, reagents, and bioinformatics infrastructure, making them unaffordable for many healthcare providers and patients. The cost burden is further exacerbated by the need for specialized expertise to interpret complex genomic data, increasing operational expenses for diagnostic laboratories and hospitals. Many low- and middle-income countries struggle to integrate genomic-based cancer diagnostics into their healthcare systems due to budget constraints and the lack of reimbursement policies for these advanced tests.
Limited accessibility to genomic cancer care is another critical issue, particularly in remote and underserved regions. Many healthcare facilities lack the necessary infrastructure to conduct in-house genomic testing, leading to delays in diagnosis and treatment initiation. Patients in such areas often need to travel long distances to access specialized centers, increasing financial and logistical burdens. The disparity in access to genomic testing is also evident within high-income countries, where only major medical centers offer comprehensive genomic profiling, while smaller hospitals and clinics face resource limitations. The absence of standardized regulations and inconsistent reimbursement policies across different regions further hinder the widespread adoption of genomic technologies in oncology.
Key Market Trends
Liquid Biopsies and Early Detection
The Global Genomics in Cancer Care Market is experiencing a significant shift toward liquid biopsies and early detection, driven by advancements in next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Liquid biopsy is emerging as a revolutionary tool for non-invasive cancer diagnostics, enabling real-time monitoring of tumor progression and treatment response. Traditional tissue biopsies are often invasive, time-consuming, and limited in capturing tumor heterogeneity. Liquid biopsies, on the other hand, provide a comprehensive genomic profile by detecting genetic alterations in circulating biomarkers such as ctDNA, circulating tumor cells (CTCs), and extracellular vesicles in blood samples. The increasing adoption of this technology is improving early cancer detection rates, enhancing treatment personalization, and reducing the need for repeated invasive procedures.
Key Market Players
- Illumina Inc
- Agilent Technologies, Inc.
- Roche Diagnostics
- Cancer Genetics, Inc.
- Bio-Rad Laboratories Inc
- Sigma-Aldrich Corp
- QIAGEN NV
- GE Healthcare Inc
- Life Technologies Corp
- Quest Diagnostics Inc
Report Scope:
In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Genomics in Cancer Care Market, By Product:
- Instruments
- Consumables
- Services
Genomics in Cancer Care Market, By Technology:
- Genome Sequencing
- PCR
- Microarray
- Nucleic Acid Extraction and Purification
- Others
Genomics in Cancer Care Market, By Application:
- Diagnostics
- Personalized Medicine
- Drug Discovery & Development
- Research
Genomics in Cancer Care Market, By End User:
- Hospitals
- Research Institutes & Academic Institutes
- Others
Genomics in Cancer Care Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Genomics in Cancer Care Market.
Available Customizations:
Global Genomics in Cancer Care market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Genomics in Cancer Care Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Instruments, Consumables, Services)
- 5.2.2. By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others)
- 5.2.3. By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research)
- 5.2.4. By End User (Hospitals, Research Institutes & Academic Institutes, Others)
- 5.2.5. By Company (2024)
- 5.2.6. By Region
- 5.3. Market Map
6. North America Genomics in Cancer Care Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Technology
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Genomics in Cancer Care Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Technology
- 6.3.1.2.3. By Application
- 6.3.1.2.4. By End User
- 6.3.2. Mexico Genomics in Cancer Care Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Technology
- 6.3.2.2.3. By Application
- 6.3.2.2.4. By End User
- 6.3.3. Canada Genomics in Cancer Care Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Technology
- 6.3.3.2.3. By Application
- 6.3.3.2.4. By End User
7. Europe Genomics in Cancer Care Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Technology
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Genomics in Cancer Care Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Technology
- 7.3.1.2.3. By Application
- 7.3.1.2.4. By End User
- 7.3.2. Germany Genomics in Cancer Care Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Technology
- 7.3.2.2.3. By Application
- 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Genomics in Cancer Care Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Technology
- 7.3.3.2.3. By Application
- 7.3.3.2.4. By End User
- 7.3.4. Italy Genomics in Cancer Care Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Technology
- 7.3.4.2.3. By Application
- 7.3.4.2.4. By End User
- 7.3.5. Spain Genomics in Cancer Care Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Technology
- 7.3.5.2.3. By Application
- 7.3.5.2.4. By End User
8. Asia-Pacific Genomics in Cancer Care Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Technology
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Genomics in Cancer Care Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Technology
- 8.3.1.2.3. By Application
- 8.3.1.2.4. By End User
- 8.3.2. India Genomics in Cancer Care Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Technology
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. South Korea Genomics in Cancer Care Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Technology
- 8.3.3.2.3. By Application
- 8.3.3.2.4. By End User
- 8.3.4. Japan Genomics in Cancer Care Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Technology
- 8.3.4.2.3. By Application
- 8.3.4.2.4. By End User
- 8.3.5. Australia Genomics in Cancer Care Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Technology
- 8.3.5.2.3. By Application
- 8.3.5.2.4. By End User
9. South America Genomics in Cancer Care Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Technology
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Genomics in Cancer Care Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Technology
- 9.3.1.2.3. By Application
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Genomics in Cancer Care Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Technology
- 9.3.2.2.3. By Application
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Genomics in Cancer Care Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Technology
- 9.3.3.2.3. By Application
- 9.3.3.2.4. By End User
10. Middle East and Africa Genomics in Cancer Care Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Technology
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Genomics in Cancer Care Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Technology
- 10.3.1.2.3. By Application
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Genomics in Cancer Care Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Technology
- 10.3.2.2.3. By Application
- 10.3.2.2.4. By End User
- 10.3.3. UAE Genomics in Cancer Care Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Technology
- 10.3.3.2.3. By Application
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porters Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Illumina Inc
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Agilent Technologies, Inc.
- 14.3. Roche Diagnostics
- 14.4. Cancer Genetics, Inc.
- 14.5. Bio-Rad Laboratories Inc
- 14.6. Sigma-Aldrich Corp
- 14.7. QIAGEN NV
- 14.8. GE Healthcare Inc
- 14.9. Life Technologies Corp
- 14.10. Quest Diagnostics Inc
15. Strategic Recommendations
16. About Us & Disclaimer
